The WuXi XDC one-stop service and technology platform provides for our clients an unmatched value chain for the development of ADCs and other bioconjugates including conjugated diagnostic and …

By offering a single-source, open-access platform with the most comprehensive capabilities and technologies, WuXi XDC enables our biopharmaceutical partners to speed the development of …

We seek to expand our discovery, development and manufacturing capabilities and capacity at the Wuxi site, to encompass the full-spectrum of services for the antibody and payload-linker intermediates …

WuXi XDC offers comprehensive and integrated discovery, CMC development and cGMP manufacturing of the payloads, linkers and payload-linker chemical intermediates used in the production of Antibody …

WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market.

Mar 7, 2025 · With proprietary conjugation and payload-linker technologies, and an integrated technology platform, WuXi XDC remains dedicated to supporting biopharmaceutical partners in …

Dec 17, 2024 · WuXi XDC’s efficient and high-quality capacity expansion is poised to address the global shortage of ADC production capacity, delivering superior biopharmaceutical solutions to clients and …

Mar 24, 2025 · WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK) is a leading global CRDMO focused on bioconjugate market. It provides end-to-end contract research, development and …

Oct 16, 2024 · WuXi XDC, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in ADCs and XDCs, today announced a significant milestone in …

Our Empowerment and Leadership in the Diversified and Innovative ADC/XDC Field More than 3,700 different ADC and XDC molecules made by us in 2024 alone